These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 29859131)

  • 1. "Exceptional brain aging" without Alzheimer's disease: triggers, accelerators, and the net sum game.
    Vemuri P
    Alzheimers Res Ther; 2018 Jun; 10(1):53. PubMed ID: 29859131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Amyloid Protective Factors and Alzheimer Disease Neurodegeneration Protective Factors in Elderly Individuals.
    Vemuri P; Knopman DS; Lesnick TG; Przybelski SA; Mielke MM; Graff-Radford J; Murray ME; Roberts RO; Vassilaki M; Lowe VJ; Machulda MM; Jones DT; Petersen RC; Jack CR
    JAMA Neurol; 2017 Jun; 74(6):718-726. PubMed ID: 28418521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies.
    Lista S; Dubois B; Hampel H
    J Nutr Health Aging; 2015 Feb; 19(2):154-63. PubMed ID: 25651440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain Aging and Late-Onset Alzheimer's Disease: A Matter of Increased Amyloid or Reduced Energy?
    Mecocci P; Baroni M; Senin U; Boccardi V
    J Alzheimers Dis; 2018; 64(s1):S397-S404. PubMed ID: 29562513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multimodal Neuroimaging in Alzheimer's Disease: Early Diagnosis, Physiopathological Mechanisms, and Impact of Lifestyle.
    Chételat G
    J Alzheimers Dis; 2018; 64(s1):S199-S211. PubMed ID: 29504542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Grading Biomarker for the Prediction of Conversion From Mild Cognitive Impairment to Alzheimer's Disease.
    Tong T; Gao Q; Guerrero R; Ledig C; Chen L; Rueckert D; Initiative ADN
    IEEE Trans Biomed Eng; 2017 Jan; 64(1):155-165. PubMed ID: 27046891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long night's journey into the day: amyloid-β imaging in Alzheimer's disease.
    Villemagne VL; Rowe CC
    J Alzheimers Dis; 2013; 33 Suppl 1():S349-59. PubMed ID: 22710919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex differences in the association between AD biomarkers and cognitive decline.
    Koran MEI; Wagener M; Hohman TJ;
    Brain Imaging Behav; 2017 Feb; 11(1):205-213. PubMed ID: 26843008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-amyloid sequelae in the eye: a critical review on its diagnostic significance and clinical relevance in Alzheimer's disease.
    Shah TM; Gupta SM; Chatterjee P; Campbell M; Martins RN
    Mol Psychiatry; 2017 Mar; 22(3):353-363. PubMed ID: 28093567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple effects of physical activity on molecular and cognitive signs of brain aging: can exercise slow neurodegeneration and delay Alzheimer's disease?
    Brown BM; Peiffer JJ; Martins RN
    Mol Psychiatry; 2013 Aug; 18(8):864-74. PubMed ID: 23164816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease (AD) therapeutics - 2: Beyond amyloid - Re-defining AD and its causality to discover effective therapeutics.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():376-401. PubMed ID: 30273552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neural substrates of cognitive reserve in Alzheimer's disease spectrum and normal aging.
    Lee DH; Lee P; Seo SW; Roh JH; Oh M; Oh JS; Oh SJ; Kim JS; Jeong Y
    Neuroimage; 2019 Feb; 186():690-702. PubMed ID: 30503934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease.
    Hays CC; Zlatar ZZ; Wierenga CE
    Cell Mol Neurobiol; 2016 Mar; 36(2):167-79. PubMed ID: 26898552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of Alzheimer's disease, tau propagation, and its modifiable risk factors.
    Takeda S
    Neurosci Res; 2019 Apr; 141():36-42. PubMed ID: 30120962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease.
    Tarawneh R; Head D; Allison S; Buckles V; Fagan AM; Ladenson JH; Morris JC; Holtzman DM
    JAMA Neurol; 2015 Jun; 72(6):656-65. PubMed ID: 25867677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Brain's Structural Connectome Mediates the Relationship between Regional Neuroimaging Biomarkers in Alzheimer's Disease.
    Pandya S; Kuceyeski A; Raj A;
    J Alzheimers Dis; 2017; 55(4):1639-1657. PubMed ID: 27911289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's Disease.
    Besson FL; La Joie R; Doeuvre L; Gaubert M; Mézenge F; Egret S; Landeau B; Barré L; Abbas A; Ibazizene M; de La Sayette V; Desgranges B; Eustache F; Chételat G
    J Neurosci; 2015 Jul; 35(29):10402-11. PubMed ID: 26203136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of lifestyle interventions on clinical and neuroimaging outcomes in elderly.
    Rolandi E; Frisoni GB; Cavedo E
    Ageing Res Rev; 2016 Jan; 25():1-12. PubMed ID: 26589097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.